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I N t r O D U c t I O N 
Adiponectin and brain natriuretic peptide (BNP) are hormones released from adi-
pocytes and myocardial cells respectively, in response to different stimuli. Adiponectin 
is the most abundant adipokine secreted by adipose tissue that may couple regulation 
of insulin sensitivity with energy metabolism. [1] Decreased plasma concentration has 
been observed in patients with diabetes, metabolic syndrome and coronary artery 
disease, and this may play a key role in the development of insulin resistance. The 
exact mechanism underlying anti–inflammatory properties of adiponectin is not yet 
well understood but there is evidence that its properties may be related, in part, to its 
ability to stimulate production of nitric oxide (NO), which is considered to be the potent 
vasodilator substance produced from endothelial cells. [2] Nowadays, adiponectin is 
increasingly recognized to be both a potential biomarker for the metabolic syndrome 
and a possible therapeutic target for the treatment of cardiovascular disease. 
Brain natriuretic peptide is one of the three major natriuretic peptides, atrial 
natriuretic peptide (ANP), B – type natriuretic peptide (BNP) and C – type natriuretic 
peptide (CNP), all of which share a common 17 – amino – acid ring structure and have 
cardioprotective actions against volume overload. [3] Although this peptide was called 
brain (B – type) natriuretic peptide (BNP), the primary site of BNP synthesis is the 
ventricular myocardium. [4] Its initial diagnostic value was attributed in its ability to 
distinguish heart failure from other causes of dyspnea. Moreover, recently BNP and 
NT–proBNP have been related to other cardiac diseases, such as stable and unstable 
angina, valvular heart disease and sudden death, adding a new angle in their diagnostic 
and prognostic roles. In this review, the prognostic role of adiponectin and BNP in 
cardiovascular diseases will be briefly presented. 
m O L E c U L A r  c H A r A c t E r I s t I c s  A N D  f U N c t I O N  O f 
A D I P O N E c t I N
The adipocyte is an active secretory cell producing several cytokines (adipokines) 
including tumor necrosis factor – α (TNF – α), interleukins, plasminogen activator 
inhibitor type 1, leptin and adiponectin. [1] Adiponectin, also called ARCP30, AdipoQ, 
apM1 and GBP28, is the most abundant adipokine and is increasingly recognized to 
be both a potential biomarker for the metabolic syndrome and a possible therapeutic 
target for the treatment of cardiovascular disease in obese patients. [5] It is a 30 – kDa 
protein which was first described in 15. It consists of an N – terminal collagenous 
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domain and a C – terminal globular domain which has struc-
tural similarities to tumor necrosis factor – α (TNF – α) [6,7]. 
The monomers of adiponectin have been shown to aggregate 
into several polymeric forms in plasma, including trimeric, 
hexameric and high – molecular weight oligomeric forms. 
Adiponectin exists in the circulation as a full length protein 
and a proteolytic smaller globular domain fragment. Plasma 
adiponectin levels in humans are quite high, normally ranging 
from 3 to 20 μg/mL and there is a strong negative correlation 
between plasma levels and body mass index, especially visceral 
adiposity. [8] The expression of adiponectin in adipose tissue 
seems to be regulated by several mechanisms via humoral and 
neuronal pathways. Two adiponectin receptors were identified 
in 2003, AdipoR1 and AdipoR2. [] The first, AdipoR1 is a 
high affinity receptor for the globular C – terminal domain 
and is expressed mainly in skeletal muscles. On the other 
hand, AdipoR2 has intermediate affinity for both forms of adi-
ponectin and is most abundant in the liver. [] T – cadherin is 
a glycosylphosphatidylinositol (GPI) – anchored extracellular 
protein and has been demonstrated as a receptor for hexameric 
and high molecular weight adiponectin but not for trimeric or 
globular adiponectin. [10]  Tissue distribution of T–cadherin 
is widespread in cardiovascular system, nervous system and 
muscle but is not highly expressed in the hepatocyte, which is 
one of the major targets of adiponectin. [11]
There are several conditions and factors that regulate the 
metabolic function of adiponectin. Thus, insulin and insu-
lin–like growth factor–1 both upregulate adiponectin expres-
sion, whereas TNF – a, PPAR – α and PPAR – γ agonists, as 
metformin and thiazolidinediones respectively, have the op-
posite effect. [12,13] Angiotensin II also reduces adiponectin 
production probably via signaling through the angiotensin II 
type 1 receptor. [14] In addition, sympathetic activation sup-
presses adiponectin expression via adrenergic β function. Most 
other factors with a significant impact on adiponectin regula-
tion have inhibitory effects. These include catecholamines, 
glucocorticoids, cytokines, prolactin, growth hormone and 
androgens. 15] Adiponectin regulates metabolism and insulin 
sensitivity, at least in part, by promoting the phosphorylation 
and activation of AMP – activated protein kinase (AMPK), 
which is a stress – responsive kinase, in skeletal muscle, liver 
and adipocytes and affects many aspects of cellular metabo-
lism including glucose uptake, glucose utilization and fatty 
acid oxidation. AMPK activation is believed to be mediated 
by adiponectin binding to the cell surface receptors AdipoR1 
and AdipoR2. [16]
A D I P O N E c t I N  A N D  c A r D I O v A s c U L A r 
D I s E A s E
Adiponectin may be the most relevant and promising 
adipokine with respect to a better understanding of the link 
between obesity and coronary heart disease. Importantly, 
low levels have been demonstrated in patients with ischemic 
heart disease (Fig. 1). In a prospective study, men with high 
adiponectin levels were at lower risk of myocardial infarction 
than those with lower levels. This association was independ-
ent of common risk factors, such as diabetes or hypertension. 
[17] Additionally, low adiponectin levels were associated 
with both carotid atherosclerosis and cardiovascular disease. 
[18] Adiponectin levels have also been reported to rapidly 
decline after acute myocardial infarction. The protective 
action of adiponectin against myocardial ischemia appears 
to be mediated by its ability to activate cyclooxygenase – 2 
(COX – 2) in cardiac cells which has been shown to play an 
important cardioprotective role. [1] These studies have ad-
ditionally demonstrated that hypoadiponectinemia seems 
to be a negative prognostic indicator for the development of 
cardiovascular disease especially in obese patients. In patients 
with acute coronary syndromes, where a vulnerable coronary 
plaque is known to be the key feature of the pathophysiologic 
process, plasma concentrations of adiponectin have been 
found significantly lower than those in patients with stable 
angina pectoris indicating thus a possible role of adiponectin 
in maintaining coronary plaque stability. [20] Consistent with 
this observation, adiponectin levels have been significantly 
associated with coronary lesion complexity especially in men 
while they have not proven to be such a good  predictor of 
coronary heart disease in women. [21]
Clinical studies have shown that patients with essential 
hypertension appear to have significantly lower plasma adi-
ponectin levels than normotensive patients. The underlying 
mechanism may be involving the effects of angiotensin II. In-
fusion of angiotensin II in rats decreased plasma adiponectin 
levels via signaling through the angiotensin II type 1 recep-
fIGUrE 1. Conditions associated with hypoadiponectinemia.
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tor. [22] Additionally, patients with essential hypertension 
treated with angiotensin II receptor antagonists or angiotensin 
– converting enzyme inhibitors, had increased adiponectin 
concentrations without affecting body mass indices. The posi-
tive correlation between adiponectin levels and hypertension 
has been found more significant in men compared to women. 
[23] Moreover, hyperadiponectinemia is positively correlated 
with high-density lipoprotein levels and negatively with triglyc-
erides and apolipoprotein (Apo) B – 100. These correlations 
remain significant even after adjusting for obesity–associated 
variables. [24] In contrast, low–density lipoprotein and total 
cholesterol do not have significant independent relationship 
to adiponectin levels. [25]
Although it is not clear how or whether adiponectin itself 
has anti–inflammatory properties, it is clear that adiponectin 
production by adipose tissue can be inhibited by systemic 
inflammation. Adiponectin production by adipocytes is inhib-
ited by inflammatory cytokines such as TNF – α in vitro and 
this process may be mediated in part by NF – kB signaling. 
Thus, adiponectin reduces the TNF–α stimulated expression 
of adhesion molecules, the expression of the pro-inflammatory 
cytokine IL – 8 in endothelial cells and inhibits the transfor-
mation of macrophages to foam cells. [26] On the other hand, 
adiponectin increases the expression of the anti-inflammatory 
cytokine IL – 10 and the tissue inhibitor of metalloproteinase 
– 1 in macrophages. [27] Moreover, it has been found that 
expression of adiponectin is inversely associated with that of 
CRP in men with coronary artery disease. 
Adiponectin seems to have beneficial effects in angiogen-
esis and endothelial function through the AMPK pathway 
in the vasculature, which has been identified as a regulator 
of endothelial cell nitric oxide synthase (eNOS) activation 
as well as a number of cellular responses important for the 
angiogenesis process. [28] Globular adiponectin increases 
eNOS both expression and activity in endothelial cells and 
improves ox – LDL induced suppression of eNOS activity. [2] 
Further studies have demonstrated the anti – apoptotic action 
of adiponectin in endothelial cells especially by inhibiting an-
giotensin II apoptosis in endothelial cells. [30] Moreover, there 
is evidence that adiponectin promotes directly the formation 
and growth of new blood vessels stimulating endothelial cell 
migration and differentiation into capillary – like structures in 
vitro through activation of AMPK signaling pathway. [28] In 
vascular lesions, adiponectin seems to suppress the prolifera-
tion of smooth muscle cells promoting vascular remodeling. 
In vitro studies have shown that adiponectin can inhibit the 
proliferation and direct migration of smooth muscle cells to 
platelet – derived growth factor – BB ameliorating this way 
the neointimal hyperplasia and proliferation following acute 
vascular injury. [31] These results are consistent with in vivo 
animal studies where adiponectin knockout mice showed an 
accelerated thrombus formation on carotid arterial injury 
with a He – Ne laser. 
s Y N t H E s I s  A N D  f U N c t I O N  O f  b r A I N 
N A t r I U r E t I c  P E P t I D E  ( b N P ) 
The brain natriuretic peptide (BNP) is synthesized in 
bursts as a preprohormone of 134 residues and constitutively 
released from ventricular myocytes when left ventricular wall 
stress increase. Then it is cleaved to yield a 108-amino-acid 
prohormone, which is further cleaved by an unknown protease 
into an inactive 76 aminoacid N – terminal fragment (NT 
– proBNP) and a 32 aminoacid active hormone (BNP). It 
must be noticed that BNP gene expression can be increased 
very rapidly in response to an appropriate stimulus such as 
tachycardia, glucocorticoids, thyroid hormones and vasoactive 
peptides angiotensisn II and endothelin – 1, independent of 
their hemodynamic effects (Fig. 2). BNP has a half – life of 
approximately 20 min, while the half – life of the more stable 
NT – proBNP is about 120 min [11]. Normal plasma levels of 
BNP and NT – proBNP vary widely and depend on both age 
and gender. For BNP, they range from a few picograms per 
milliliter in young males to higher than 100 pg/ml in appar-
ently healthy females over 70 years old. For acutely dyspneic 
patients, some have suggested cutoffs of BNP<100 pg/ml and 
NT – proBNP<300 pg/ml to rule out heart failure. The biologi-
cal actions of BNP are mediated through membrane – bound 
natriuretic peptide receptors A (NPRs – A) that are linked 
to a cyclic guanosine monophosphate – dependent signaling 
cascade. NT – proBNP is eliminated mainly through kidney 
clearance, while BNP is mostly eliminated either through bind-
ing to its receptors NPRs – A or via degradation by neutral 
endopeptidase that is present on the surface of endothelial 
cells. However, renal failure is associated with elevations in 
both BNP and NT – proBNP levels. In general, BNP and NT 
– proBNP are reasonably correlated and both of them can 
be used in the routine clinical practice accordingly to each 
clinician’s decision.
fIGUrE 2. Effects of Brain Natriuretic Peptide (BNP).
202
HOSPITAL CHRONICLES, SUPPLEMENT 2008
b N P  A s  P r O G N O s t I c  b I O m A r K E r  f O r 
c A r D I O v A s c U L A r  D I s E A s E
Both BNP and NT – proBNP can predict death and car-
diovascular events in patients presenting with acute or chronic 
heart failure (HF) and they are being studied as a possible 
screening tool. [3] It must be noted that pooled results from 
five studies showed that a BNP increase of 100 pg per mL was 
associated with a 35% increase in risk of death. [32] BNP was 
the only statistically significant independent predictor of mor-
tality in nine studies, indicating that BNP tests potentially are 
more useful than traditional predictors of mortality (e.g., age, 
ischemic etiology, left ventricular ejection fraction, NYHA 
classification, serum creatinine levels). [32] Data from the 
multicenter prospective study REDHOT (Rapid ED Heart 
Failure Outpatient Trial) showed that in patients with HF 
admitted to emergency department, BNP was predictive of 
future HF events and mortality and outperformed physician 
assessment, which had a poor predictive value. [33] Moreover, 
the response of plasma BNP to therapy was illustrated in a 
study enrolling 102 patients with severe HF who were stud-
ied at baseline and three months after optimized treatment 
including ACE inhibitors, beta blockers and digoxin. Opti-
mized therapy was associated with significant reductions in 
plasma BNP (17 at baseline to 285 pg/mL) as well as in other 
neurohumoral factors such as norepinephrine. [34] Addition-
ally, data from Val–HeFT (Valsartan Heart Failure Trial) 
indicate that in 4300 patients with congestive HF, those with 
the greatest increase in BNP despite medical therapy had the 
highest morbidity and mortality. [35] Moreover, several studies 
have indicated the usefulness of BNP in predicting the risk 
of sudden death. Particularly, in 452 patients with severe left 
ventricular dysfunction (ejection fraction <35%) only 1% of 
patients with BNP <130 pg/mL died suddenly compared with 
1% of patients with BNP ≥130 pg/mL. [36] In addition, in 
multivariate analyses BNP was more closely associated with 
mortality than was NYHA class or left ventricular ejection 
fraction. It must be noted that BNP, beyond its relationship to 
sudden cardiac death, may be also associated with re-hospitali-
zations, a setting in which traditional risk factors do not have 
any prognostic value. Furthermore, it is known that plasma 
BNP and NT – proBNP levels are lower in obese patients but 
despite this phenomenon, plasma BNP retains its prognostic 
value in this group of patients. [37]
Although natriuretic peptides BNP and NT – proBNP 
most often are used in patients with dyspnea and those with 
established HF, their plasma concentrations have been im-
plicated as predicting markers in a variety of other cardiac 
diseases. Thereby, acute coronary syndromes have been associ-
ated with a rise in BNP and NT – proBNP levels even in the 
absence of concomitant heart failure. The degree of elevation 
might reflect the severity of left ventricular dysfunction. [38] 
In a study that enrolled 1085 patients with stable coronary 
artery disease for a mean follow up about 2,5 years, BNP and 
ejection fraction were the strongest predictors of future events, 
independent of known risk factors. Plasma NT – proBNP 
appears to have equivalent predictive value in these patients. 
[3] In the AtheroGene study data provided independent evi-
dence that BNP was a strong predictor of cardiovascular risk 
in patients with stable angina independent of left ventricular 
systolic performance and known risk factors. [40]
The prognosting importance of plasma BNP in patients 
presenting with acute coronary syndromes was best illustrated 
in a study of 2525 patients with unstable angina and non – ST 
elevation myocardial infarction in whom plasma BNP was 
measured about 40 hours after the onset of symptoms. After 
adjusting for other predictors of risk, such as renal function, 
electrocardiographic changes, and troponin I levels, BNP was 
reputedly capable to assess the long-term risk of death and 
nonfatal cardiac events across the spectrum of acute coronary 
syndromes. [41] Furthermore, persistent elevation of NT 
– proBNP 3 to 6 months after an acute coronary syndrome 
has been associated with impaired left ventricular function. 
Moreover, in a study that enrolled 4266 patients with acute 
coronary syndrome, those with elevated levels of BNP at study 
entry and with BNP levels lower than 80 pg/mL at 4 months 
tended to have only modestly increased risk (HR, 1.7; 5% CI, 
1.0-2.) compared with patients with BNP levels lower than 
80 pg/mL at both visits. [42] The largest study of NT–proBNP 
in acute coronary syndromes comes from the analysis of data 
on 680 patients presented with non–ST elevation myocardial 
infarction, in the GUSTO IV ACS trial. According to this 
analysis, NT–proBNP illustrated a stronger correlation with 
mortality than any other marker studied, including cTnT 
and CRP. In this study, patients within 24 hours of symptom 
onset with NT – proBNP values ≤8 ng/L had a significantly 
lower mortality rate at one year than those with values ≥4634 
ng/L. [43]
Natriuretic peptides have been considered a useful clinical 
tool for monitoring patients suffering from valvular disease be-
fore and after surgery. Raised levels of BNP and NT – proBNP 
have been positively correlated with the severity of valvular 
disease. In particular, among patients with aortic stenosis 
these peptides may be a useful adjunct to classify patients 
with equivocal symptoms who are at risk for rapid progression. 
[44] In patients who undergo surgical valve replacement or 
conservative management, natriuretic peptides levels might 
predict survival and postoperative left ventricular function. 
Also, there has been shown a significantly positive correlation 
between low levels of BNP and the risk of postoperative atrial 
fibrillation. [46] In chronic aortic regurgitation, BNP levels 
tend to rise less than in aortic stenosis even when left ventricu-
lar dilatation has occurred. [47] With respect to mitral valve 
disorders, BNP was shown to be a marker of poor outcome in 
a study of 124 patients with mitral regurgitation, where levels 
were independently predictive of death. [48]  
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c O N c L U s I O N s
Adiponectin and BNP are targets for future research 
as prognostic markers of morbidity and mortality in several 
cardiovascular diseases. Interventions increasing adiponectin 
levels are weight loss and the administration of insulin sen-
sitizers, such as thiazolidinediones. More research is needed 
in this field as well. As we mentioned above, the beneficial 
effects of adiponectin in the atherosclerosis cascade and the 
development of cardiovascular disease are not completely 
undrerstood and future research is needed to clarify its 
pathophysiologic role.  
On the other hand, BNP levels increase in several condi-
tions affecting left ventricular function, so their measurement, 
especially in asymptomatic patients, might be a useful clini-
cal tool even for the primary care physician. It is expected 
that within the next few years BNP and NT – proBNP will 
find clinical application not only in the assessment of the 
severity and the progression rate of heart failure, but also of 
other cardiovascular diseases such as unstable angina and 
valvular heart disease. The major limitation for using BNP 
as a prognostic biomarker is that specific therapeutic strate-
gies for patients with raised concentrations have not yet been 
widely available.   
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